+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour



Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour



Investigational New Drugs 28(2): 199-202




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053506148

Download citation: RISBibTeXText

PMID: 19352594

DOI: 10.1007/s10637-009-9249-1


Related references

Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Annals of Oncology 19(11): 1975, 2008

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. Journal of Urology 179(1): 81-6; Discussion 86, 2007

Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma. Reports of Practical Oncology and RadioTherapy 21(4): 361-369, 2016

Antiangiogenic therapy: preclinical premise and promise: Biological Basis for Antiangiogenic Therapy, Milan, Italy, 810 November 1999. Molecular Medicine Today 6(5): 188-189, 2000

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. Medical Oncology 34(10): 167, 2018

Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor. Journal of Clinical Oncology 26(15_Suppl): 10512-10512, 2016

Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab. Actas Dermo-Sifiliograficas 105(10): 900-912, 2016

Aortic dissection during antiangiogenic therapy with sunitinib. A case report. Sao Paulo Medical Journal 133(3): 275-277, 2016

Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy. Biochemical and Biophysical Research Communications 413(1): 128-135, 2011

Antiangiogenic therapy of a relapsed neuroblastoma with interferon alfa-2a. Proceedings of the American Association for Cancer Research Annual Meeting (41): 260-261, 2000

Antiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis. Translational Oncology 7(2): 221-229, 2014

Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration. Lancet. Oncology 2018, 2018

Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?. Annals of Oncology 22(6): 1247-1249, 2011

Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?. Journal of Oncology Pharmacy Practice 2018: 1078155218799850, 2018

Antiangiogenic tumour therapy: will it work?. Trends in Pharmacological Sciences 19(6): 216-222, 1998